Myositis : From classification to diagnosis
Copyright © 2020 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved..
Idiopathic inflammatory myopathies, or IIM, are a group of acquired diseases that affect the muscle to a certain extent, and may also affect other organs. They include dermatomyositis, which can affect the muscle eventualy, with a typical skin rash; inclusion body myositis, with a purely muscular expression resulting in a slow progressive deficit; and the former group of "polymyositis", a misnomer that actually includes other categories of IIM, such as immune-mediated necrotizing myopathies, with a severe muscle involvement often presents from the onset of the disease; antisynthetase syndrome, which combines muscle damage, joint involvement and a potentially life-threatening lung disease; and overlapping myositis, which combines muscle damage with other organs involvement connected to another autoimmune disease. The diagnosis of IIM is based on rigorous clinical examination and interrogation, electromyographic data and immunological testing for myositis specific antibodies. This antibody dosage must be extended or repeated if necessary to classify correctly the muscle disease under investigation, as the available tests may not perform well enough. Muscle biopsy, although very informative, is not anymore systematically recommended when the clinic and the antibodies are typical. However, some forms of IIM are sometimes difficult to classify; in these cases, muscle biopsy plays a crucial role in the precise etiological diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
La Revue de medecine interne - 42(2021), 6 vom: 08. Juni, Seite 392-400 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Myosites : de la classification au diagnostic |
|---|
| Beteiligte Personen: |
Fer, F [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.11.2021 Date Revised 24.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.revmed.2020.10.379 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318152622 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318152622 | ||
| 003 | DE-627 | ||
| 005 | 20231225164747.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.revmed.2020.10.379 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318152622 | ||
| 035 | |a (NLM)33248855 | ||
| 035 | |a (PII)S0248-8663(20)30774-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Fer, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myositis |b From classification to diagnosis |
| 246 | 3 | 3 | |a Myosites : de la classification au diagnostic |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.11.2021 | ||
| 500 | |a Date Revised 24.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Idiopathic inflammatory myopathies, or IIM, are a group of acquired diseases that affect the muscle to a certain extent, and may also affect other organs. They include dermatomyositis, which can affect the muscle eventualy, with a typical skin rash; inclusion body myositis, with a purely muscular expression resulting in a slow progressive deficit; and the former group of "polymyositis", a misnomer that actually includes other categories of IIM, such as immune-mediated necrotizing myopathies, with a severe muscle involvement often presents from the onset of the disease; antisynthetase syndrome, which combines muscle damage, joint involvement and a potentially life-threatening lung disease; and overlapping myositis, which combines muscle damage with other organs involvement connected to another autoimmune disease. The diagnosis of IIM is based on rigorous clinical examination and interrogation, electromyographic data and immunological testing for myositis specific antibodies. This antibody dosage must be extended or repeated if necessary to classify correctly the muscle disease under investigation, as the available tests may not perform well enough. Muscle biopsy, although very informative, is not anymore systematically recommended when the clinic and the antibodies are typical. However, some forms of IIM are sometimes difficult to classify; in these cases, muscle biopsy plays a crucial role in the precise etiological diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticorps spécifique des myosites | |
| 650 | 4 | |a Antisynthetase | |
| 650 | 4 | |a Antisynthétase | |
| 650 | 4 | |a Dermatomyosite | |
| 650 | 4 | |a Dermatomyositis | |
| 650 | 4 | |a Inflammatory myopathy | |
| 650 | 4 | |a Myopathie inflammatoire | |
| 650 | 4 | |a Myosite | |
| 650 | 4 | |a Myositis | |
| 650 | 4 | |a Myositis-specific antibodies | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Allenbach, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Benveniste, O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t La Revue de medecine interne |d 1983 |g 42(2021), 6 vom: 08. Juni, Seite 392-400 |w (DE-627)NLM012660108 |x 1768-3122 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2021 |g number:6 |g day:08 |g month:06 |g pages:392-400 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.revmed.2020.10.379 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2021 |e 6 |b 08 |c 06 |h 392-400 | ||